WO2001027612A3 - Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl - Google Patents

Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl Download PDF

Info

Publication number
WO2001027612A3
WO2001027612A3 PCT/EP2000/010057 EP0010057W WO0127612A3 WO 2001027612 A3 WO2001027612 A3 WO 2001027612A3 EP 0010057 W EP0010057 W EP 0010057W WO 0127612 A3 WO0127612 A3 WO 0127612A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
antigen
acid
complex
resistant microorganisms
Prior art date
Application number
PCT/EP2000/010057
Other languages
English (en)
French (fr)
Other versions
WO2001027612A2 (de
Inventor
Christian Reiter
Gerhard Cullmann
Meret Lakner
Andreas Truee
Sonja Dehnert
George Schwartz
Original Assignee
Connex Ges Zur Optimierung Von
Christian Reiter
Gerhard Cullmann
Meret Lakner
Andreas Truee
Sonja Dehnert
George Schwartz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27439941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001027612(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Connex Ges Zur Optimierung Von, Christian Reiter, Gerhard Cullmann, Meret Lakner, Andreas Truee, Sonja Dehnert, George Schwartz filed Critical Connex Ges Zur Optimierung Von
Priority to JP2001530572A priority Critical patent/JP2003511697A/ja
Priority to US10/110,410 priority patent/US7129053B1/en
Priority to AU11373/01A priority patent/AU1137301A/en
Priority to EP00972748A priority patent/EP1221045A2/de
Publication of WO2001027612A2 publication Critical patent/WO2001027612A2/de
Publication of WO2001027612A3 publication Critical patent/WO2001027612A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zum Nachweis einer Infektion eines Säugers mit einem Säure-resistenten Mikroorganismus, das folgende Schritte umfaßt : (a) Bereitstellen eines immunchromatographischen Tests mit einem Probenauftragbereich zum Auftragen einer Stuhlprobe des Säugers mit einem Antigen und Auftragen der Stuhlprobe, (b) Inkubieren der Stuhlprobe unter Verwendung (i) eines ersten Rezeptors unter Bedingungen, die eine Komplexbildung des Antigens aus dem Säure-resistenten Mikroorganismus mit dem Rezeptor erlauben; oder (ii) mindestens zweier unterschiedlicher erster Rezeptoren unter Bedingungen, die eine Komplexbildung des Antigens aus dem Säure-resistenten Mikroorganismus mit den mindestens zwei ersten Rezeptoren erlauben und wobei der erste Rezeptor gemäß (i) oder die ersten Rezeptoren gemäß (ii) ein Antigen spezifisch bindet/binden, das zumindest bei einem Teil der Säuger nach der Darmpassage eine Struktur aufweist, die der nativen Struktur oder der Struktur entspricht, gegen die ein Säuger nach Infektion oder Immunisierung mit dem Säure-resistenten Mikroorganismus oder einem Extrakt oder Lysat davon oder einem Protein daraus oder einem Fragment davon oder einem synthetischen Peptid Antikörper produziert, (c) Bereitstellen eines an einem Analysebereich immobilisierten zweiten Rezeptors, wobei der zweite Rezeptor einen Antigen-Rezeptorkomplex gemäß (b) bindet, und (d) Transportieren und Nachweisen der Bildung mindestens eines Antigen-Rezeptorkomplexes gemäß (b) durch Akkumulieren des Antigen-Rezeptorkomplexes an dem zweiten Rezeptor im Analysebereich. Die Erfindung betrifft ferner einen immunchromatographischen Test, der insbesondere geeignet bzw. ausgebildet ist, um das erfindungsgemäße Verfahren durchzuführen.
PCT/EP2000/010057 1999-10-12 2000-10-12 Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl WO2001027612A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001530572A JP2003511697A (ja) 1999-10-12 2000-10-12 便中の酸耐性微生物を検出するためのイムノクロマトグラフィー迅速試験
US10/110,410 US7129053B1 (en) 1999-10-12 2000-10-12 Immuno-chromatographic rapid assay in order to detect acid-resistant microorganisms in the stool
AU11373/01A AU1137301A (en) 1999-10-12 2000-10-12 Immuno-chromatographic rapid assay in order to detect acid-resistant microorganisms in the stool
EP00972748A EP1221045A2 (de) 1999-10-12 2000-10-12 Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP99120351 1999-10-12
EP99120351.4 1999-10-12
EP00105592 2000-03-16
EP00105592.0 2000-03-16
EP00107028.3 2000-03-31
EP00107028 2000-03-31
EP00110110.4 2000-05-10
EP00110110 2000-05-10

Publications (2)

Publication Number Publication Date
WO2001027612A2 WO2001027612A2 (de) 2001-04-19
WO2001027612A3 true WO2001027612A3 (de) 2001-10-11

Family

ID=27439941

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2000/010057 WO2001027612A2 (de) 1999-10-12 2000-10-12 Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl
PCT/EP2000/010058 WO2001027613A2 (de) 1999-10-12 2000-10-12 Verbessertes verfahren zum nachweis von säure-resistenten mikroorganismen im stuhl

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010058 WO2001027613A2 (de) 1999-10-12 2000-10-12 Verbessertes verfahren zum nachweis von säure-resistenten mikroorganismen im stuhl

Country Status (16)

Country Link
US (1) US7129053B1 (de)
EP (2) EP1232392B2 (de)
JP (2) JP2003511698A (de)
CN (1) CN1382259A (de)
AT (1) ATE236398T1 (de)
AU (2) AU1137301A (de)
BR (1) BR0014734A (de)
CA (1) CA2387473C (de)
DE (1) DE50001665D1 (de)
DK (1) DK1232392T3 (de)
ES (1) ES2194782T5 (de)
IL (1) IL149062A0 (de)
PT (1) PT1232392E (de)
SI (1) SI1232392T1 (de)
TR (1) TR200201006T2 (de)
WO (2) WO2001027612A2 (de)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008036B2 (en) 1999-12-17 2011-08-30 Curemark, Llc Method for identifying autistic individuals amenable to digestive enzyme therapy
US8012710B2 (en) 2000-08-14 2011-09-06 Curemark, Llc Methods of treating and diagnosing Parkinsons disease and related dysautonomic disorders
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US8815156B2 (en) 2010-07-19 2014-08-26 Andalyze, Inc. Sensor housing and reagent chemistry
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1227159B1 (de) * 1999-10-29 2011-04-20 Wakamoto Pharmaceutical Co., Ltd. Monoklonaler antikörper, hybridoma, immuntestverfahren und diagnosekit
JP3504633B2 (ja) 1999-10-29 2004-03-08 わかもと製薬株式会社 ヘリコバクター・ピロリへの感染を判定する検査方法及び検査試薬
US6706474B1 (en) 2000-06-27 2004-03-16 Board Of Trustees Of The University Of Illinois Nucleic acid enzyme biosensors for ions
WO2002014541A1 (en) * 2000-08-11 2002-02-21 Wakamoto Pharmaceutical Co., Ltd. Method of examining infection with helicobacter pylori and diagnostic kit
JP4763149B2 (ja) * 2001-05-10 2011-08-31 わかもと製薬株式会社 ヘリコバクター・ピロリへの感染を判定する検査方法
FI118061B (fi) 2001-09-24 2007-06-15 Beanor Oy Menetelmä ja bioanturi analyysiä varten
FI115166B (fi) * 2001-12-31 2005-03-15 Biofons Oy Diagnostisia menetelmiä
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
BR122019027974B1 (pt) 2002-05-02 2022-06-14 Wyeth Holdings Corporation Composição compreendendo conjugado monomérico de derivado de caliqueamicina/anticorpo anti-cd22 e seu uso
US7534560B2 (en) 2002-05-10 2009-05-19 The Board Of Trustees Of The University Of Illinois Simple catalytic DNA biosensors for ions based on color changes
US6890719B2 (en) 2002-05-10 2005-05-10 The Board Of Trustess Of The University Of Illinois Fluorescence based biosensor
US7612185B2 (en) 2003-03-07 2009-11-03 The Board Of Trustees Of The University Of Illinois Nucleic acid biosensors
WO2005012531A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
CA2548381C (en) * 2003-12-05 2015-12-01 Fuso Pharmaceutical Industries, Ltd. Cytolethal distending toxins and detection of campylobacter bacteria using the same as a target
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
US7485419B2 (en) 2004-01-13 2009-02-03 The Board Of Trustees Of The University Of Illinois Biosensors based on directed assembly of particles
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
EP1686378B1 (de) * 2005-01-28 2010-11-17 DNT Scientific Research, LLC Durchflussdiffusor für immunologische Testvorrichtungen und Verfahren
CN101351710B (zh) 2005-04-04 2013-06-05 生物基因Idecma公司 评价对治疗性蛋白质的免疫应答的方法和产品
EP2594591B1 (de) * 2005-08-11 2018-06-06 Arpi Matossian-Rogers Tcr-v-beta-bezogene peptide für die behandlung und diagnose einer autoimmunerkrankung
US7892734B2 (en) 2005-08-11 2011-02-22 The Board Of Trustees Of The University Of Illinois Aptamer based colorimetric sensor systems
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
WO2007024633A2 (en) * 2005-08-23 2007-03-01 Response Biomedical Corporation Multi-directional immunochromatographic assays
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
ES2663377T3 (es) 2006-03-03 2018-04-12 Biogen Ma Inc. Métodos para el tratamiento de enfermedades inflamatorias y autoinmunes con natalizumab
WO2007109500A1 (en) * 2006-03-16 2007-09-27 The Board Of Trustees Of The University Of Illinois Lateral flow devices
US8415461B2 (en) 2007-01-19 2013-04-09 The Board Of Trustees Of The University Of Illinois Amphiphilic substances and functionalized lipid vesicles including the same
US8058415B2 (en) 2007-04-24 2011-11-15 The Board Of Trustees Of The University Of Illinois Aptamer- and nucleic acid enzyme-based systems for simultaneous detection of multiple analytes
ES2374686T3 (es) 2007-05-14 2012-02-21 Historx, Inc. Separación en compartimentos por caracterización de píxel usando agrupamiento de datos de imágenes.
US7907271B2 (en) 2007-06-15 2011-03-15 Historx, Inc. Method and system for standardizing microscope instruments
WO2009012309A2 (en) 2007-07-16 2009-01-22 The Board Of Trustees Of The University Of Illinois Nucleic acid based fluorescent sensor for divalent copper ion detection
US8568690B2 (en) 2007-07-31 2013-10-29 The Board Of Trustees Of The University Of Illinois MRI contrast agents and high-throughput screening by MRI
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
US8367416B2 (en) 2007-08-10 2013-02-05 The Board Of Trustees Of The University Of Illinois Nucleic acid based fluorescent sensor for mercury detection
WO2009029810A1 (en) 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
CA2737116C (en) 2008-09-16 2019-01-15 Historx, Inc. Reproducible quantification of biomarker expression
US8062893B2 (en) 2008-10-10 2011-11-22 The Board Of Trustees Of The University Of Illinois Fluorescent sensor for mercury
WO2011044553A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
DK2524060T3 (en) 2010-01-11 2018-03-12 Biogen Ma Inc ASSAY FOR JC VIRUS ANTIBODIES
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
CN102539424B (zh) * 2011-12-23 2013-11-20 李雄 一种pH值乙醇法舌苔快速尿素酶的检测方法及试剂盒
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
CN102980884A (zh) * 2012-11-29 2013-03-20 江苏创生生物技术有限公司 胃黏膜样品中幽门螺旋杆菌的化学发光免疫测定法
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
SG11201704550XA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
US10823726B2 (en) 2015-10-21 2020-11-03 Redcoat Solutions, Inc. Bed bugs detection device
PL3365367T3 (pl) 2015-10-21 2023-10-30 Redcoat Solutions, Inc. Przeciwciała monoklonalne przeciwko pluskwom oraz metody ich wytwarzania i zastosowania
NZ743124A (en) * 2015-12-04 2022-11-25 Memorial Sloan Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
US20210333273A1 (en) 2018-03-30 2021-10-28 Biomedical Research Institute Co., Ltd. Laboratory test kit and method for using the laboratory test kit
CN111499751B (zh) * 2020-05-06 2021-03-19 云南省农业科学院园艺作物研究所 一种用于检测白菜过氧化氢酶的单克隆抗体及其应用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN113388616B (zh) * 2021-07-27 2022-04-26 中国海洋大学 特异性结合幽门螺旋杆菌的核酸适配体、生物元件、生物传感器及检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291194A1 (de) * 1987-04-27 1988-11-17 Unilever N.V. Immunoassays und Vorrichtungen dafür
US5712170A (en) * 1992-12-29 1998-01-27 Oy Medix Biochemica Ab Test strip, its production and use
US5932430A (en) * 1996-05-09 1999-08-03 Meridian Diagnostics, Inc. Immunoassay for H. pylori in fecal specimens
WO1999044066A1 (en) * 1998-02-25 1999-09-02 Helitech Biomedical Inc. Encapsulated diagnostics for alimentary analytes
WO2000026671A1 (de) * 1998-10-29 2000-05-11 Connex Gmbh Nachweis von säure-resistenten mikroorganismen im stuhl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
US5607863A (en) * 1991-05-29 1997-03-04 Smithkline Diagnostics, Inc. Barrier-controlled assay device
CA2117430A1 (en) * 1992-02-21 1993-09-02 Richard Katz Brofaromine as an agent for treating post-traumatic stress
JP3448071B2 (ja) * 1992-03-24 2003-09-16 ロート製薬株式会社 糞便中ヘモグロビン検出用装置
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
SE9600949D0 (sv) * 1996-03-12 1996-03-12 Stefan Svenson Method of diagnosing a mycobacterial disease and immunoassay kit
US5716791A (en) 1996-05-09 1998-02-10 Meridian Diagnostics, Inc. Immunoassay for H. pylori in fecal specimens
IT1289578B1 (it) * 1996-12-06 1998-10-15 Sanitaria Scaligera Spa Immunopurificazione di un antigene dall'apparente peso molecolare di 16 +- 2 kda dell' helicobacter pylori e metodi per la sua
AU3458299A (en) * 1998-03-31 1999-10-18 United States Of America, As Represented By The Secretary Of Agriculture, The Monoclonal antibodies against (campylobacter jejuni) and (campylobacter coli) outer membrane antigens
US6433728B1 (en) 1999-01-22 2002-08-13 Lear Automotive Dearborn, Inc. Integrally molded remote entry transmitter

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291194A1 (de) * 1987-04-27 1988-11-17 Unilever N.V. Immunoassays und Vorrichtungen dafür
US5712170A (en) * 1992-12-29 1998-01-27 Oy Medix Biochemica Ab Test strip, its production and use
US5932430A (en) * 1996-05-09 1999-08-03 Meridian Diagnostics, Inc. Immunoassay for H. pylori in fecal specimens
WO1999044066A1 (en) * 1998-02-25 1999-09-02 Helitech Biomedical Inc. Encapsulated diagnostics for alimentary analytes
WO2000026671A1 (de) * 1998-10-29 2000-05-11 Connex Gmbh Nachweis von säure-resistenten mikroorganismen im stuhl

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAHEIJ R J F ET AL: "Evaluation of commercially available Helicobacter pylori serology kits: A review.", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 36, no. 10, October 1998 (1998-10-01), pages 2803 - 2809, XP002160659, ISSN: 0095-1137 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8613918B2 (en) 1999-12-17 2013-12-24 Curemark Llc Method for treating pervasive development disorders
US8012930B2 (en) 1999-12-17 2011-09-06 Curemark, Llc Methods of treating pervasive development disorders
US8105584B2 (en) 1999-12-17 2012-01-31 Curemark Llc Method for treating pervasive development disorders
US8163278B2 (en) 1999-12-17 2012-04-24 Curemark Llc Methods for treating pervasive development disorders
US8211661B2 (en) 1999-12-17 2012-07-03 Curemark, Llc Method for identifying individuals having a pervasive development disorder amenable to digestive enzyme therapy
US8008036B2 (en) 1999-12-17 2011-08-30 Curemark, Llc Method for identifying autistic individuals amenable to digestive enzyme therapy
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US8012710B2 (en) 2000-08-14 2011-09-06 Curemark, Llc Methods of treating and diagnosing Parkinsons disease and related dysautonomic disorders
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US9377459B2 (en) 2000-11-16 2016-06-28 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9408895B2 (en) 2008-03-13 2016-08-09 Curemark, Llc Method of treating pregnancy-induced hypertension
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8318158B2 (en) 2008-04-18 2012-11-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US8486390B2 (en) 2008-04-18 2013-07-16 Curemark Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9415014B2 (en) 2009-04-13 2016-08-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US8815156B2 (en) 2010-07-19 2014-08-26 Andalyze, Inc. Sensor housing and reagent chemistry
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9492515B2 (en) 2011-04-21 2016-11-15 Curemark, Llc Method of treatment of schizophreniform disorder

Also Published As

Publication number Publication date
US7129053B1 (en) 2006-10-31
IL149062A0 (en) 2002-11-10
WO2001027613A3 (de) 2001-10-18
CA2387473A1 (en) 2001-04-19
BR0014734A (pt) 2002-06-18
CN1382259A (zh) 2002-11-27
EP1232392B2 (de) 2014-04-02
AU7787100A (en) 2001-04-23
AU1137301A (en) 2001-04-23
CA2387473C (en) 2010-02-02
DE50001665D1 (de) 2003-05-08
JP2003511697A (ja) 2003-03-25
JP2003511698A (ja) 2003-03-25
EP1336850A1 (de) 2003-08-20
PT1232392E (pt) 2003-08-29
EP1232392A1 (de) 2002-08-21
TR200201006T2 (tr) 2002-11-21
ES2194782T3 (es) 2003-12-01
EP1232392B1 (de) 2003-04-02
WO2001027612A2 (de) 2001-04-19
ATE236398T1 (de) 2003-04-15
SI1232392T1 (en) 2003-10-31
ES2194782T5 (es) 2014-08-20
WO2001027613A2 (de) 2001-04-19
DK1232392T3 (da) 2003-07-28

Similar Documents

Publication Publication Date Title
WO2001027612A3 (de) Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl
US4228237A (en) Methods for the detection and determination of ligands
Selo et al. Preferential labeling of α-amino N-terminal groups in peptides by biotin: application to the detection of specific anti-peptide antibodies by enzyme immunoassays
US10048280B2 (en) Immunoassay for the detection of procalcitonin
EP2853898A1 (de) Analyse von Myostatin im Serum
EP1734366A3 (de) Neues Verfahren zum Nachweis von Säure-resistenten Mikroorganismen im Stuhl
WO2001009190A3 (en) Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
WO2008125733A8 (en) Immunoassay for quantification of an unstable antigen selected from bnp and probnp
Paul et al. Enzyme-linked immunosorbent assays for sperm antibody detection and antigenic analysis
KR880003004A (ko) 재조합 htlv-ⅲ 단백질 및 이의 용도
US10634676B2 (en) Method and kit for simultaneously detecting human parvovirus B19 antigen and antibody
Grassi et al. Two different approaches for developing immunometric assays of haptens
EP3531129B1 (de) Immuntestverfahren unter verwendung eines anti-humanen bnp-fragment (4-32)-antikörpers
Hashida et al. Detection of one attomole of [Arg8]-vasopressin by novel noncompetitive enzyme immunoassay (hetero-two-site complex transfer enzyme immunoassay)
EP0331514A3 (de) Prüfung der Deletion oder des Mangels an Protein von Duchenne-Muskeldystrophie
FI119990B (fi) N-peptidin kerrosimmuunimääritysmenetelmä
JP6357425B2 (ja) 干渉ペプチド及び微生物の検出方法
Nara et al. Use of biotin–streptavidin system for developing a viable, sensitive and specific antigen heterologous assay for hapten
CN114910643B (zh) 一种鉴别结合突变型抗原的抗体的方法及试剂
US10024872B2 (en) Augurin immunoassay
Tanaka et al. Novel and sensitive noncompetitive enzyme immunoassay to measure peptides by biotinylation
Wang et al. Development of A Monoclonal Antibody‐Based Competitive Elisa Method for Quantitative Detection of Dextran
Sohi et al. The use of camel antibodies in development of EGFRvIII enzyme-linked immunosorbent assay
WO2000040967A3 (de) Verfahren und vorrichtung zur diagnose allergischer symptome
JPH1189569A (ja) モノクローナル抗体産生細胞ライン及びその作製方法、並びにモノクローナル抗体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000972748

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00348/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2001 530572

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000972748

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10110410

Country of ref document: US

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)